Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Response to First-Line Treatment in Patients with N/K T-Cell Lymphoma. Experience of a Third Level Mexican Institute

Katheryn Betsabe Garzón, MD, Silvia Rivas-Vera, MD, Brenda L. Acosta-Maldonado, MD

Blood (2019) 134 (Supplement_1): 5286.

https://doi.org/10.1182/blood-2019-129887

Published: 2019

Journal Articles

Rituximab Combined Therapy and Maintenance Eliminate the Follicular Lymphoma with MYC Translocation

Anna Nishihara, MD, Yuko Mishima, PhD, Tomoko Takayama, Yasuhito Terui, MD PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Hirofumi Yamauchi, MD, Norihito Inoue, MD, Naoko Tsuyama, MD PhD, Yuji Mishima, PhD, Kengo Takeuchi, MDPhD, Kiyohiko Hatake, MD PhD

Blood (2017) 130 (Supplement 1): 2784.

https://doi.org/10.1182/blood.V130.Suppl_1.2784.2784

Published: 2017

Journal Articles

Combined therapy in MCL: less may be more?

Martin Dreyling

Blood (2016) 128 (14): 1782–1783.

https://doi.org/10.1182/blood-2016-07-726505

Published: 2016

Journal Articles

Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells

John A Valenta, M.S., Warren Fiskus, Ph.D, Taghi Manshouri, Ph.D., Sunil Sharma, MD, Jun Qi, PhD, Leasha J Schaub, M.S., Bhavin Shah, Melissa Rodriguez, M.D., Ph.D, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, Srdan Verstovsek, MD, PhD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 2842.

https://doi.org/10.1182/blood.V122.21.2842.2842

Published: 2013

Journal Articles

Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD

Melissa Rodriguez, M.D., Ph.D, Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S., Bhavin Shah, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 3821.

https://doi.org/10.1182/blood.V122.21.3821.3821

Published: 2013

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

Kapil Bhalla, MD, Warren Fiskus, Ph.D., Stephen K. Horrigan, PhD, Sunil Abhyankar, MD, Joseph McGuirk, DO, Sunil Sharma, MD

Blood (2012) 120 (21): 287.

https://doi.org/10.1182/blood.V120.21.287.287

Published: 2012

Journal Articles

The Impact of Race, Age, and Sex in Chronic Lymphocytic Leukemia (CLL): A Comprehensive SEER Analysis in the Pre and Post Rituximab (R) Eras.

Chadi Nabhan, MD, FACP, Briseis Aschebrook-Kilfoy, Ph. D., Andrew M. Evens, DO, MSc, Brian C-H Chiu, Ph.D., Sonali M. Smith, MD, Tait D. Shanafelt, MD, Neil E. Kay, MD

Blood (2012) 120 (21): 2877.

https://doi.org/10.1182/blood.V120.21.2877.2877

Published: 2012

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

Warren Fiskus, Ph.D., Sunil Sharma, M.D., Sunil Abhyankar, MD, Joseph McGuirk, DO, David J. Bearss, PhD, Kapil Bhalla, MD

Blood (2012) 120 (21): 868.

https://doi.org/10.1182/blood.V120.21.868.868

Published: 2012

Journal Articles

How I treat transfusional iron overload

A. Victor Hoffbrand, Ali Taher, Maria Domenica Cappellini

Blood (2012) 120 (18): 3657–3669.

https://doi.org/10.1182/blood-2012-05-370098

Published: 2012

Journal Articles

Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial

Carmelo Carlo-Stella, MD, Anna Guidetti, MD, Simonetta Viviani, MD, Liliana Devizzi, MD, Paola Matteucci, MD, Alfonso Marchianò, MD, Rodolfo Lanocita, MD, Stefania Zambelli, MD, Roberto Sorasio, MD, Massimo Di Nicola, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD

Blood (2010) 116 (21): 2861.

https://doi.org/10.1182/blood.V116.21.2861.2861

Published: 2010

Journal Articles

Favourable Outcome of B-Cell Non Hodgkin Lymphomas Associated with Hepatitis C Virus - ANRS HC13 LYMPHO-C Observational Study

Caroline Besson, Danielle Canioni, MD, Catherine Settegrana, Henda Driss, Laurent Alric, Cyrille Feray, Felipe Suarez, Florence N Guyen Khac, Helene Merle-Beral, Patrice Cacoub, Frederic Davi, Olivier Hermine, MD, PhD

Blood (2010) 116 (21): 3116.

https://doi.org/10.1182/blood.V116.21.3116.3116

Published: 2010

Journal Articles

Treatment of Sezary Syndrome with Combined Therapy

Giorgio Corinaldesi, MD, PhD

Blood (2010) 116 (21): 4928.

https://doi.org/10.1182/blood.V116.21.4928.4928

Published: 2010

Journal Articles

Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study

Franco Dammacco, Felicia Anna Tucci, Gianfranco Lauletta, Pietro Gatti, Valli De Re, Vincenza Conteduca, Silvia Sansonno, Sabino Russi, Maria Addolorata Mariggiò, Maria Chironna, Domenico Sansonno

Blood (2010) 116 (3): 343–353.

https://doi.org/10.1182/blood-2009-10-245878

Published: 2010

Journal Articles

Antitumor Activity of Small-Molecule SYK Inhibitor R788 and Fludarabinin Mono- and Combined Therapy in a Human B-CLL Xenograft Model.

Julia Schüler, Maike Buchner, Heinz-Herbert Fiebig, Hendrik Veelken, Katja Zirlik, MD

Blood (2009) 114 (22): 2378.

https://doi.org/10.1182/blood.V114.22.2378.2378

Published: 2009

Journal Articles

Functional PRAME Specific T Cells Can Be Cultured From CD8+ Cells From Healthy Donors but Not From Patients at First CR: Implications for Immunotherapeutic Strategies in AML.

Willemijn van den Ancker, Theresia M Westers, PhD, Hetty J Bontkes, PhD, Dewi Wulandari, Erik Hooijberg, PhD, Anita GM Stam, Saskia JAM Santegoets, PhD, Gert J Ossenkoppele, MD, PhD, Tanja D de Gruijl, PhD, Arjan A van de Loosdrecht, MD, PhD

Blood (2009) 114 (22): 4139.

https://doi.org/10.1182/blood.V114.22.4139.4139

Published: 2009

Journal Articles

Cytoreductive Combined Therapy in Essential Thrombocythemia Patients: Report of the Registro Italiano Trombocitemia (RIT)

Potito Rosario Scalzulli, MD, Alessia Tieghi, MD, Anna Marina Liberati, MD, Monica Crugnola, MD, Giorgina Specchia, MD, Emma Cacciola, MD, Rosanna Ciancia, MD, Anna Candoni, MD, Enrico Balleari, MD, Roberto Latagliata, MD, Marta Gubbiotti, MD, Maria Rosa Valvano, Lorella Melillo, MD, Nicola Cascavilla, MD, Luigi Gugliotta, MD

Blood (2008) 112 (11): 5243.

https://doi.org/10.1182/blood.V112.11.5243.5243

Published: 2008

Journal Articles

Combined Therapy with Lenalidomide and Prednisone Renders Durable Clinical, Histopathological, and Molecular Responses in Patients with Myelofibrosis

AlFonso Quintas-Cardama, MD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Jorge Cortes, MD, Farhad Ravandi, MBBS, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Neda Bell, Catriona Byrne, Srdan Verstovsek

Blood (2008) 112 (11): 662.

https://doi.org/10.1182/blood.V112.11.662.662

Published: 2008

Journal Articles

A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy with Deferoxamine and Deferiprone on Myocardial Iron in Thalassaemia Major Using Cardiovascular Magnetic Resonance.

Mark A. Tanner, MD, Renzo Galanello, MD, Carlo Dessi, MD, Mark A. Westwood, MD, Gillian C. Smith, MSc, Mohammed Khan, MSc, Sunil V. Nair, MD, J. M. Walker, MD, Dudley J. Pennell, MD

Blood (2005) 106 (11): 3655.

https://doi.org/10.1182/blood.V106.11.3655.3655

Published: 2005

Journal Articles

Combined Therapy with Alemtuzumab and Pentostatin Is Feasible and Effective in T- Lymphoprolifertive Disorders.

Farhad Ravandi-Kashani, MD, Hagop Kantarjian, MD, Srdan Verstovsek, MD, PhD, Alessandra Ferrajoli, MD, William Wierda, MD, PhD, Shirley Odinga, Xueling Huang, Sherry Pierce, Stefan Faderl, MD, Francis Giles, MD, Susan O’Brien, MD, Michael Keating, MD

Blood (2005) 106 (11): 5024.

https://doi.org/10.1182/blood.V106.11.5024.5024

Published: 2005

NARROW

Response to First-Line Treatment in Patients with N/K T-Cell Lymphoma. Experience of a Third Level Mexican Institute

Rituximab Combined Therapy and Maintenance Eliminate the Follicular Lymphoma with MYC Translocation

Combined therapy in MCL: less may be more?

Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells

Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

The Impact of Race, Age, and Sex in Chronic Lymphocytic Leukemia (CLL): A Comprehensive SEER Analysis in the Pre and Post Rituximab (R) Eras.

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

How I treat transfusional iron overload

Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial

Favourable Outcome of B-Cell Non Hodgkin Lymphomas Associated with Hepatitis C Virus - ANRS HC13 LYMPHO-C Observational Study

Treatment of Sezary Syndrome with Combined Therapy

Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study

Antitumor Activity of Small-Molecule SYK Inhibitor R788 and Fludarabinin Mono- and Combined Therapy in a Human B-CLL Xenograft Model.

Functional PRAME Specific T Cells Can Be Cultured From CD8+ Cells From Healthy Donors but Not From Patients at First CR: Implications for Immunotherapeutic Strategies in AML.

Cytoreductive Combined Therapy in Essential Thrombocythemia Patients: Report of the Registro Italiano Trombocitemia (RIT)

Combined Therapy with Lenalidomide and Prednisone Renders Durable Clinical, Histopathological, and Molecular Responses in Patients with Myelofibrosis

A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy with Deferoxamine and Deferiprone on Myocardial Iron in Thalassaemia Major Using Cardiovascular Magnetic Resonance.

Combined Therapy with Alemtuzumab and Pentostatin Is Feasible and Effective in T- Lymphoprolifertive Disorders.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only